SARS-CoV-2 Papain-like Protease (PLpro) complex with covalent inhibitor Jun13567

2-Gaussian fit: Grosse-Kunstleve RW, Sauter NK, Adams PD: Newsletter of the IUCr Commission on Crystallographic Computing 2004, 3, 22-31.

1-Gaussian fit: Grosse-Kunstleve RW, Sauter NK, Adams PD: Newsletter of the IUCr Commission on Crystallographic Computing 2004, 3, 22-31.

Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors.

Non-structural protein 3,nsp3,PL2-PRO,Papain-like proteinase,PL-PRO

SNAEVRTIKVFTTVDNINLHTQVVDMSMTYGQQFGPTYLDGADVTKIKPHNSHEGKTFYVLPNDDTLRVEAFEYYHTTDP
SFLGRYMSALNHTKKWKYPQVNGLTSIKWADNNCYLATALLTLQQIELKFNPPALQDAYYRARAGEAANFCALILAYCNK
TVGELGDVRETMSYLFQHANLDSCKRVLNVVCKTCGQQQTTLKGVEAVMYMGTLSYEQFKKGVQIPCTCGKQATKYLVQQ
ESPFVMMSAPPAQYELKHGTFTCASEYTGNYQCGHYKHITSKETLYCIDGALLTKSSEYKGPITDVFYKENSYTTTIK

Severe acute respiratory syndrome coronavirus 2

200 mM zinc acetate, 0.1 M Bis-Tris pH 5.5-6.6, 10% PEG 8000

National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)

SARS CoV-2, Papain-like Protease (PLpro), Covalent inhibitor, Jun13567, VIRAL PROTEIN, HYDROLASE-INHIBITOR complex

(chain "A" and (resid 4 or (resid 5 and (name N or name CA or name C or name O or name CB )) or resid 6 through 47 or (resid 48 and (name N or name CA or name C or name O or name CB )) or resid 49 through 52 or (resid 53 and (name N or name CA or name C or name O or name CB )) or resid 54 through 84 or resid 86 through 173 or resid 175 through 184 or (resid 185 and (name N or name CA or name C or name O or name CB )) or resid 198 through 214 or (resid 215 and (name N or name CA or name C or name O or name CB )) or resid 216 or (resid 217 and (name N or name CA or name C or name O or name CB )) or resid 218 or (resid 231 through 234 and (name N or name CA or name C or name O or name CB )) or resid 235 through 296 or (resid 297 and (name N or name CA or name C or name O or name CB )) or resid 298 through 312))

(chain "B" and (resid 4 through 84 or resid 86 through 173 or resid 175 through 312))

EVRTIKVFTTVDNINLHTQVVDMSMTYGQQFGPTYLDGADVTKIKPHNSHEGKTFYVLPNDDTLRVEAFEYYHTTDPSFL
GRYMSALNHTKKWKYPQVNGLTSIKWADNNCYLATALLTLQQIELKFNPPALQDAYYRARAGEAANFCALILAYCNKTVG
ELGDVRETMSYLFQHANLDSCKRVLNVVCKTCGQQQTTLKGVEAVMYMGTLSYEQFKKGVQIPCTCGKQATKYLVQQESP
FVMMSAPPAQYELKHGTFTCASEYTGNYQCGHYKHITSKETLYCIDGALLTKSSEYKGPITDVFYKENSYTTTIK